Figure 5.

Impaired proteolytic processing of von Willebrand factor upon loss of APOLD1. (A) Immunoblotting of lysates from mock and chloroquine-treated (25 mM for 12 h) control or APOLD1 siRNA-treated human dermal blood endothelial cells (HDBEC) with subsequent densitometric quantification of (B) proteolytic VWF processing, (C) SQSTM1 and (D) LC3B I/II expression. Immunoblots are representative of at least three independent experiments. Bar graphs in (B-D) represent the mean ± standard deviation. Two-way analysis of variance followed by the Sidak multiple comparison test, ***P<0.001.